BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30458966)

  • 1. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Melbourne Consensus Statement on the early detection of prostate cancer.
    Murphy DG; Ahlering T; Catalona WJ; Crowe H; Crowe J; Clarke N; Cooperberg M; Gillatt D; Gleave M; Loeb S; Roobol M; Sartor O; Pickles T; Wootten A; Walsh PC; Costello AJ
    BJU Int; 2014 Feb; 113(2):186-8. PubMed ID: 24206066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA-based screening for localised prostate cancer. Uncertain benefits, potential adverse consequences, and many outstanding questions.
    Prescrire Int; 2009 Oct; 18(103):225. PubMed ID: 19882799
    [No Abstract]   [Full Text] [Related]  

  • 5. Guideline of guidelines: prostate cancer screening.
    Loeb S
    BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current aspects of prostate cancer screening].
    Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
    Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Braillon A; Dubois G
    J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
    [No Abstract]   [Full Text] [Related]  

  • 10. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is the mass screening for prostate cancer justifiable?].
    Döbrossy L; Kovács A; Budai A; Cornides A
    Orv Hetil; 2007 Jul; 148(26):1213-6. PubMed ID: 17588854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In depth analysis of 2 studies of prostate cancer screening--what makes sense?].
    Recker F
    Praxis (Bern 1994); 2010 Feb; 99(3):183-5. PubMed ID: 20127638
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnosis and overdiagnosis of prostate cancer: a personal view.
    Tam PC
    Hong Kong Med J; 2012 Dec; 18(6):456-8. PubMed ID: 23223644
    [No Abstract]   [Full Text] [Related]  

  • 17. The implementation of screening for prostate cancer.
    van Leeuwen PJ; van Vugt HA; Bangma CH
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):218-27. PubMed ID: 20680029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
    Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC
    J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.
    Boyle P
    Ann Oncol; 1998 Dec; 9(12):1263-4. PubMed ID: 9932152
    [No Abstract]   [Full Text] [Related]  

  • 20. [Indirect consequences of PSA testing for prostate cancer screening].
    Naïmi R; Senglet M; De Gorski A; Kherad O
    Rev Med Suisse; 2020 Feb; 16(680):275-277. PubMed ID: 32022494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.